Get ready for a game-changer in the world of influenza vaccines! The battle against influenza just got a major upgrade. Apriori Bio, a pioneer in variant-resilient vaccines, has joined forces with ASTAR Infectious Diseases Labs (ASTAR IDL) to create next-generation vaccines that will revolutionize protection against seasonal and pandemic flu.
This strategic partnership combines Apriori's cutting-edge Octavia™ platform, which predicts viral evolution, with A*STAR IDL's expertise in RNA delivery technology. Together, they aim to develop improved H5 influenza vaccines that anticipate and combat human infections.
Craig Williams, CEO of Apriori Bio, emphasizes the significance of this collaboration: "We're taking a giant leap forward in vaccine design by harnessing AI to predict and protect against evolving viruses like influenza. With A*STAR IDL's RNA delivery capabilities, we're on a mission to provide lasting immunity for patients worldwide."
Professor Lisa Ng, Executive Director of A*STAR IDL, adds, "Our collaboration reflects a shared vision to turn research into real-world solutions. By combining forces, we aim to accelerate vaccine development and enhance global preparedness for future outbreaks."
But here's where it gets controversial... Harry Kleanthous, Chief Scientific Officer of Apriori Bio, highlights the limitations of current H5 influenza vaccines, stating, "Existing vaccines struggle to provide robust single-dose immunity and broad protection against emerging variants. saRNA offers a promising solution, and when combined with our Octavia™-generated antigen sequences, we believe we can create the first anticipatory H5 vaccine."
Ms. Irene Cheong, Assistant Chief Executive of A*STAR Innovation and Enterprise, further emphasizes the potential impact: "This partnership brings together RNA and vaccine science expertise to better protect populations and strengthen global health security. We're thrilled to partner with Flagship Pioneering to advance cutting-edge solutions for human health."
The collaboration is part of Flagship Pioneering's institutional partnership with A*STAR, aimed at driving breakthrough innovations in biotechnology and positioning Singapore as a global hub for biotechnological advancements.
About Apriori Bio: Apriori Bio is at the forefront of AI-enabled vaccine design, aiming to improve global health outcomes. Their unique Octavia™ platform predicts viral evolution and assesses vaccine performance before clinical trials, offering a pioneering approach to vaccine development.
About ASTAR IDL: ASTAR Infectious Diseases Labs was established in 2021 with a mission to lead in infectious disease research, focusing on antimicrobial resistance, respiratory, and vector-borne diseases. A*STAR IDL brings together diverse expertise to drive innovative solutions for detection, intervention, and prevention of infectious diseases, contributing to Singapore's national defense against emerging infections.
For more information and media inquiries, please contact:
Apriori Media Contact: [email protected]
A*STAR Media Contact: Aileen Tan, Manager, Corporate Communications, +65 9186 6450, [email protected]
SOURCE Apriori Bio
